Private equity investing showing signs of rebound
The Federal Reserve’s plan to begin reducing interest rates in 2024 will likely unleash private equity’s pent-up demand for physician practices and other healthcare services companies. “Everybody wants to transact,” said Bret Schiller, managing director and head of healthcare in corporate client banking at J.P. Morgan. “I think that, at the first rate cut we…
Hospitals reached steadier ground financially as they moved into 2024
Hospitals came into 2024 with some financial momentum, even as expenses continued to rise and pivotal decisions loomed. The year-to-date median hospital operating margin reached 2.3% in December, the high mark for 2023 and the 10th consecutive month in which margins were positive, according to monthly data from Syntellis Performance Solutions, part of Strata Decision…
As healthcare defragments, payers grow stronger
Two professional memories from the past two decades come to mind as I look to the horizon and try to see where this industry is headed, as all healthcare investors must do. The first memory is of the constant refrain I heard from healthcare executives in Nashville, Tennessee, as I was learning the ropes of…
Saudi Arabia’s 2030 Transformation Goals Address Many Healthcare Finance Topics
HFMA recently spoke with Ahmed Emad Al-Hamalawy, executive director, at Selat, the parent company of NAWA, about Saudi Arabia’s Healthcare Transformation 2030 goals and the critical skills necessary for success in healthcare finance and RCM fields. NAWA was the exclusive sponsor of an HFMA one-day education training at the Global Health Exhibition (GHE) in Riyadh…
Thriving post-reset: Payer-provider partnerships after the pandemic
In the pre-pandemic era, payer-provider partnerships were often focused on aspirational goals of creating partnership value by managing costs of care and delivering high-quality care. Payers and providers aimed to drive differentiation and growth through these partnerships. In today’s more challenging macro-economic environment, these conversations are becoming more direct and practical, with both payers and…
David Johnson: The perils and possibilities of healthcare apps
In March of 2022, I coauthored a commentary titled “Healthcare’s final frontier: Engaging customers.” It contained this tongue-in-cheek Star Trek reference: “[H]ealthcare is now boldly going where most industries have gone before — into full-fledged consumer engagement.” Wanting full-fledged consumer engagement and making it happen are not synonymous. In the best of healthcare times, providers…
Summary: 10 vital responses to healthcare disruption
Note: This article is a summary of a report on HFMA’s Spring Thought Leadership Retreat. The full report is available to download. Disruption is reverberating throughout the healthcare industry, and it’s incumbent on legacy organizations to develop strategic responses for the benefit of their consumers, their communities and themselves. With that overarching challenge becoming ever…
4 points healthcare leaders should consider in their cyberinsurance calculus
In spring of 2023, two ransomware groups, Cl0p (or CLOP, per the U.S. Cybersecurity & Infrastructure Agency) and LockBit, attacked 130 organizations in the United States, many of them in healthcare.a Fortunately for healthcare organizations with cybersecurity insurance, those breaches would have been eligible for coverage. Yet the same may not have been true for…
10 Vital Responses to Healthcare Disruption
Disruption is reverberating throughout the healthcare industry, and it’s incumbent on legacy organizations to develop strategic responses for the benefit of their consumers, their communities and themselves. With that overarching challenge becoming ever more pressing, HFMA’s 2023 Spring Thought Leadership Retreat brought together leaders from across the industry May 4-5 in Atlanta to consider approaches…
Annual Conference: Healthcare entrepreneur Alex Oshmyansky describes his efforts to disrupt drug pricing
Arguably no segment of the healthcare industry is more susceptible to disruption than the market for prescription drugs, as Alex Oshmyansky, MD, PhD, made clear Wednesday morning during the closing session of HFMA’s Annual Conference. Oshmyansky spoke about his personal efforts to disrupt the pharmaceutical market in his role as co-founder and CEO of Mark…